Human Psychopharmacology: Clinical and Experimental
July 12, 2002
A. C. Parrott, Tom Buchanan, Andrew Scholey et al.
163 citations
Abstract Rationale The recreational use of MDMA/Ecstasy (3,4‐methylenedioxymethamphetamine) is associated with many psychobiological problems, but there is a paucity of data on how these relate to the level of past use. Objectives: to assess the incidence of Ecstasy‐attributed problems as reported by novice, moderate and heavy users. Methods: 763 unpaid volunteers took part in a WWW study of...
Pharmacology & Toxicology
July 2002
Marco Gesi, Paola Soldani, Paola Lenzi et al.
The acute toxicity induced by 3,4-methylenedioxymethamphetamine appears as rabdomyolysis involving the myocardium (myocytolysis) and it is often suspected to be responsible for sudden death. In line with this, cardiac symptoms such as tachycardia, hypertension, and arrhythmia are present in persons abusing ecstasy. In most cases, ecstasy is abused in loud noise, which in itself might affect the...
The Quarterly journal of medicine
July 1, 2002
T. K. Hartung
122 citations
MDMA can cause life-threatening hyponatraemic encephalopathy when accompanied by excessive fluid ingestion. The mechanism involves inappropriate secretion of antidiuretic hormone.
Journal of Psychoactive Drugs
June 1, 2002
Karen Mcelrath, Kieran McEvoy
56 citations
Similar to other sociological studies of Ecstasy use, the authors' research suggests that Ecstasy users tend to report positive effects of the drug. However, we also observed that most users experienced at least one adverse psychological outcome while using Ecstasy. The present study examines those negative experiences within the context of drug, set and setting. Data were collected through...
American Journal of Health-System Pharmacy
June 1, 2002
Kelly M. Smith, Lisa L. Larive, Frank Romanelli
226 citations
The abuse of methylenedioxymethamphetamine (MDMA), flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate (GHB) is discussed. Club drugs are chemical substances used recreationally in social settings. Use is increasingly frequent among young people, especially during all-night dance parties. All four agents have been classified as controlled substances. MDMA ("ecstasy") is available...
Annals of the New York Academy of Sciences
June 1, 2002
Jerrold S. Meyer, Syed F. Ali
25 citations
A bstract : The abused drug 3,4‐methylenedioxymethamphetamine (MDMA) damages fine serotonergic fibers and nerve terminals in adult organisms; however, developing animals seem less susceptible to this effect. One proposed hypothesis is that neonates are less sensitive to MDMA neurotoxicity because they fail to show drug‐induced hyperthermia. We tested this hypothesis by producing hyperthermia in...
Annals of the New York Academy of Sciences
June 1, 2002
B. Gough, Syed Z. Imam, Bruce E. Blough et al.
47 citations
A bstract : Paramethoxyamphetamine (PMA) is a methoxylated phenethylamine derivative that has been used illicitly in Australia since 1994. PMA is also becoming popular at rave parties in the United States. PMA raised concern when a series of fatalities resulted after its use in South Australia, where it was marketed as “ecstasy,” which is the colloquial name for MDMA. In the present study, we...
Annals of the New York Academy of Sciences
June 1, 2002
Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al.
58 citations
A bstract : Acute administration of 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) produces time‐dependent immune dysfunction in humans. Recreational use of MDMA generally includes repeated drug consumption, often in association with other drugs, such as alcohol and cannabis. In the laboratory setting, repeated MDMA administration to healthy MDMA consumers produced a time‐dependent immune...
Annals of the New York Academy of Sciences
June 1, 2002
John K. Fallon, Dhwanil Shah, Andrew T. Kicman et al.
54 citations
A bstract : 3,4‐Methylenedioxymethamphetamine (MDMA) has been reported to cause hyponatraemia, which appears to result from inappropriate secretion of the antidiuretic hormone arginine vasopressin (AVP). After administration of a low dose of ( R,S )‐MDMA (40 mg) to eight healthy drug‐free male volunteers, concentrations of AVP in plasma increased significantly at 1, 2, and 4 hours. Although no...
Journal of Psychoactive Drugs
June 1, 2002
Rick Doblin
98 citations
The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment. These studies, the...